AcelRx Pharmaceuticals (NASDAQ:ACRX) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) in a research note published on Friday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

ACRX has been the topic of several other research reports. HC Wainwright dropped their target price on AcelRx Pharmaceuticals from $8.00 to $5.00 and set a buy rating on the stock in a report on Monday, September 25th. Alliance Global Partners started coverage on AcelRx Pharmaceuticals in a report on Monday, October 2nd. They set a buy rating and a $4.25 price objective on the stock.

AcelRx Pharmaceuticals Trading Up 1.3 %

Shares of NASDAQ ACRX opened at $0.50 on Friday. The stock has a market cap of $8.49 million, a P/E ratio of -0.22 and a beta of 0.44. The business’s fifty day simple moving average is $0.60 and its 200-day simple moving average is $0.87. AcelRx Pharmaceuticals has a 12-month low of $0.43 and a 12-month high of $2.78.

Institutional Investors Weigh In On AcelRx Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC purchased a new position in shares of AcelRx Pharmaceuticals during the 1st quarter worth approximately $27,000. Virtu Financial LLC purchased a new stake in shares of AcelRx Pharmaceuticals during the 2nd quarter valued at $29,000. Cowen AND Company LLC purchased a new stake in shares of AcelRx Pharmaceuticals during the 3rd quarter valued at $67,000. Values First Advisors Inc. grew its stake in shares of AcelRx Pharmaceuticals by 201.7% during the 2nd quarter. Values First Advisors Inc. now owns 122,441 shares of the specialty pharmaceutical company’s stock valued at $136,000 after buying an additional 81,854 shares during the period. Finally, Susquehanna International Group LLP acquired a new position in shares of AcelRx Pharmaceuticals during the 4th quarter valued at $144,000. Institutional investors and hedge funds own 19.79% of the company’s stock.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain.